BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15330168)

  • 1. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
    Lans TE; Van Horssen R; Eggermont AM; Ten Hagen TL
    Anticancer Res; 2004; 24(4):2243-8. PubMed ID: 15330168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
    Kayton ML; Libutti SK
    Curr Opin Investig Drugs; 2001 Jan; 2(1):136-8. PubMed ID: 11527006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis.
    Berger AC; Alexander HR; Tang G; Wu PS; Hewitt SM; Turner E; Kruger E; Figg WD; Grove A; Kohn E; Stern D; Libutti SK
    Microvasc Res; 2000 Jul; 60(1):70-80. PubMed ID: 10873516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII).
    Wu PC; Alexander HR; Huang J; Hwu P; Gnant M; Berger AC; Turner E; Wilson O; Libutti SK
    Cancer Res; 1999 Jan; 59(1):205-12. PubMed ID: 9892208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II).
    Berger AC; Alexander HR; Wu PC; Tang G; Gnant MF; Mixon A; Turner ES; Libutti SK
    Cytokine; 2000 Jul; 12(7):992-1000. PubMed ID: 10880244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis.
    Murray JC; Heng YM; Symonds P; Rice K; Ward W; Huggins M; Todd I; Robins RA
    J Leukoc Biol; 2004 May; 75(5):772-6. PubMed ID: 14982944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization.
    van Horssen R; Rens JA; Schipper D; Eggermont AM; ten Hagen TL
    Apoptosis; 2006 Dec; 11(12):2137-45. PubMed ID: 17051333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes.
    van Horssen R; Eggermont AM; ten Hagen TL
    Cytokine Growth Factor Rev; 2006 Oct; 17(5):339-48. PubMed ID: 16945568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells.
    Tandle AT; Mazzanti C; Alexander HR; Roberts DD; Libutti SK
    Cytokine; 2005 Jun; 30(6):347-58. PubMed ID: 15935955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
    Reznikov AG; Chaykovskaya LV; Polyakova LI; Kornelyuk AI
    Exp Oncol; 2007 Dec; 29(4):267-71. PubMed ID: 18199981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.
    van Horssen R; Rens JA; Brunstein F; Guns V; van Gils M; Hagen TL; Eggermont AM
    Int J Cancer; 2006 Sep; 119(6):1481-90. PubMed ID: 16615114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
    Lans TE; ten Hagen TL; van Horssen R; Wu PC; van Tiel ST; Libutti SK; Alexander HR; Eggermont AM
    Ann Surg Oncol; 2002 Oct; 9(8):812-9. PubMed ID: 12374666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial-monocyte-activating polypeptide II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3.
    Hou Y; Plett PA; Ingram DA; Rajashekhar G; Orschell CM; Yoder MC; March KL; Clauss M
    Exp Hematol; 2006 Aug; 34(8):1125-32. PubMed ID: 16863920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of EMAP II by hypoxia.
    Matschurat S; Knies UE; Person V; Fink L; Stoelcker B; Ebenebe C; Behrensdorf HA; Schaper J; Clauss M
    Am J Pathol; 2003 Jan; 162(1):93-103. PubMed ID: 12507893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress.
    Barnett G; Jakobsen AM; Tas M; Rice K; Carmichael J; Murray JC
    Cancer Res; 2000 Jun; 60(11):2850-7. PubMed ID: 10850427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
    Yamamoto M; Fukushima T; Ueno Y; Hayashi S; Kimura H; Soma G; Tomonaga M
    Anticancer Res; 2000; 20(6A):4081-6. PubMed ID: 11131676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-neoplastic activity of low-dose endothelial-monocyte activating polypeptide-II results from defective autophagy and G2/M arrest mediated by PI3K/Akt/FoxO1 axis in human glioblastoma stem cells.
    Liu J; Liu L; Xue Y; Meng F; Li S; Wang P; Liu Y
    Biochem Pharmacol; 2014 Jun; 89(4):477-89. PubMed ID: 24792437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Meth A fibrosarcoma derived EMAP II on dendritic cell migration.
    Haridas S; Bowers M; Tusano J; Mehojah J; Kirkpatrick M; Burnham DK
    Cytokine; 2008 Nov; 44(2):304-9. PubMed ID: 18951814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.